Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Melanoma and MAPK Pathways
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
53,907
Works
1,132,764
Citations
IDs:OpenAlex
How has Melanoma and MAPK Pathways's publication output changed over time?
ScholarIQpublication output · 2011–2016
Output declined50% over the shown period — from 2 works in 2011 to 1 in 2016.
2
1
1
1
1
20112012201420152016
Who are the most-cited researchers behind Melanoma and MAPK Pathways?
ScholarIQtop researchers by citations
What are the most-cited papers on Melanoma and MAPK Pathways?
ScholarIQmost cited works
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Célèste Lebbé, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven O’Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dréno, K. B. Nolop, Jiang Li, B. Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
New England Journal of Medicine. 20117,715 CitationsOPEN ACCESS
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto
New England Journal of Medicine. 20145,365 CitationsOPEN ACCESS
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok
New England Journal of Medicine. 20114,475 CitationsOPEN ACCESS
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo, Jesse M. Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu‐Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley H. Lomeli, Xiangju Kong, Mark C. Kelley, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Roger S. Lo
Cell. 20163,569 CitationsOPEN ACCESS
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi
New England Journal of Medicine. 20152,774 CitationsOPEN ACCESS
Where is Melanoma and MAPK Pathways research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
Cell3,569
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Melanoma and MAPK Pathways is open access?
ScholarIQopen access share
100%OPEN ACCESS
Gold
0%
Green
17%
Hybrid
0%
Bronze
83%
Closed
0%
Who collaborates most closely around Melanoma and MAPK Pathways?
ScholarIQco-authorship network
United States
45%
France
18%
Italy
18%
Australia
9%
Germany
9%